BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 15519713)

  • 1. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
    Yannelli JR; Wroblewski JM
    Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell therapy: achievements and perspectives.
    Bordignon C; Carlo-Stella C; Colombo MP; De Vincentiis A; Lanata L; Lemoli RM; Locatelli F; Olivieri A; Rondelli D; Zanon P; Tura S
    Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cell therapy in solid tumors].
    Ravaud A
    Bull Cancer; 2001 Jan; 88(1):91-100. PubMed ID: 11182658
    [No Abstract]   [Full Text] [Related]  

  • 4. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive cellular therapy.
    Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
    Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

  • 7. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
    Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
    Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 9. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
    Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
    Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular immunotherapy of cancer.
    Yang JC
    Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control mechanisms of cell-mediated reactions.
    Salerno A; Sireci G; Dominici R; Bonanno CT; Caccamo N; Dieli F
    Wien Klin Wochenschr; 1996; 108(8):244-7. PubMed ID: 8686315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.
    Li B; Ding J; Larson A; Song S
    In Vivo; 1999; 13(5):433-8. PubMed ID: 10654199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA transfected dendritic cells as cancer vaccines.
    Mitchell DA; Nair SK
    Curr Opin Mol Ther; 2000 Apr; 2(2):176-81. PubMed ID: 11249639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.
    Wang Y; Chen H; Wu M; Bao J; Cong W; Wang H
    Chin Med J (Engl); 1997 Feb; 110(2):114-7. PubMed ID: 9594281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies.
    Kim S; Haas GP; Hillman GG
    Cytokines Mol Ther; 1996 Mar; 2(1):13-9. PubMed ID: 9384685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
    Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
    Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
    Mallmann P; Krebs D
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new therapeutic concept in the treatment of metastatic cancers of the kidney: the TIL (tumor infiltrating lymphocytes)].
    Peyret C
    J Urol (Paris); 1991; 97(2):63-71. PubMed ID: 2071925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How much help does a vaccine-induced T-cell response need?
    Weber JS; Mulé JJ
    J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
    [No Abstract]   [Full Text] [Related]  

  • 20. Adoptive cellular immunotherapy of cancer: future perspectives.
    Stevenson HC
    Immunol Ser; 1989; 48():229-36. PubMed ID: 2488324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.